南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2015年
1期
51-55
,共5页
张静%丁艳苓%陈亚红%姚婉贞
張靜%丁豔苓%陳亞紅%姚婉貞
장정%정염령%진아홍%요완정
过敏毒素%C3a%诱导痰%哮喘
過敏毒素%C3a%誘導痰%哮喘
과민독소%C3a%유도담%효천
anaphylatoxin%C3a%pulmanory disease%asthma
目的：研究诱导痰中过敏毒素C3a在支气管哮喘发病中的变化特点及临床意义。方法自2006年9月~2007年2月于我院呼吸科门诊和病房就诊的哮喘急性发作期患者共33例，收集其人口学资料、病史及家族史、肺功能数据及诱导痰中C3a水平，进行分析和总结。结果（1）哮喘急性发作期诱导痰中C3a水平[2.24（1.68~5.58）ng/ml]高于治疗后哮喘临床缓解期C3a水平[0.7（0.24~2.31）ng/ml]（P<0.01），哮喘临床缓解期C3a水平高于对照组[0.12（0.07~0.39）ng/ml]（P<0.05）；（2）哮喘急性发作期，诱导痰C3a水平随轻度急性发作[0.25（0.09~0.40）ng/ml]、中度急性发作[2.21（1.16~3.41）ng/ml]、重度急性发作[4.69（2.69~6.59）ng/ml]依次升高，且存在明显差异（P<0.01）；（3）哮喘急性发作期组患者诱导痰C3a水平与诱导痰细胞总数呈正相关（r=0.718, P<0.05），嗜酸性粒细胞计数呈正相关（r=0.495, P<0.05），巨噬细胞计数呈正相关（r=0.600, P<0.05）。结论诱导痰C3a水平与哮喘严重程度和局部炎症细胞学分类相关，可能成为重要的临床标志物指导哮喘的治疗。
目的：研究誘導痰中過敏毒素C3a在支氣管哮喘髮病中的變化特點及臨床意義。方法自2006年9月~2007年2月于我院呼吸科門診和病房就診的哮喘急性髮作期患者共33例，收集其人口學資料、病史及傢族史、肺功能數據及誘導痰中C3a水平，進行分析和總結。結果（1）哮喘急性髮作期誘導痰中C3a水平[2.24（1.68~5.58）ng/ml]高于治療後哮喘臨床緩解期C3a水平[0.7（0.24~2.31）ng/ml]（P<0.01），哮喘臨床緩解期C3a水平高于對照組[0.12（0.07~0.39）ng/ml]（P<0.05）；（2）哮喘急性髮作期，誘導痰C3a水平隨輕度急性髮作[0.25（0.09~0.40）ng/ml]、中度急性髮作[2.21（1.16~3.41）ng/ml]、重度急性髮作[4.69（2.69~6.59）ng/ml]依次升高，且存在明顯差異（P<0.01）；（3）哮喘急性髮作期組患者誘導痰C3a水平與誘導痰細胞總數呈正相關（r=0.718, P<0.05），嗜痠性粒細胞計數呈正相關（r=0.495, P<0.05），巨噬細胞計數呈正相關（r=0.600, P<0.05）。結論誘導痰C3a水平與哮喘嚴重程度和跼部炎癥細胞學分類相關，可能成為重要的臨床標誌物指導哮喘的治療。
목적：연구유도담중과민독소C3a재지기관효천발병중적변화특점급림상의의。방법자2006년9월~2007년2월우아원호흡과문진화병방취진적효천급성발작기환자공33례，수집기인구학자료、병사급가족사、폐공능수거급유도담중C3a수평，진행분석화총결。결과（1）효천급성발작기유도담중C3a수평[2.24（1.68~5.58）ng/ml]고우치료후효천림상완해기C3a수평[0.7（0.24~2.31）ng/ml]（P<0.01），효천림상완해기C3a수평고우대조조[0.12（0.07~0.39）ng/ml]（P<0.05）；（2）효천급성발작기，유도담C3a수평수경도급성발작[0.25（0.09~0.40）ng/ml]、중도급성발작[2.21（1.16~3.41）ng/ml]、중도급성발작[4.69（2.69~6.59）ng/ml]의차승고，차존재명현차이（P<0.01）；（3）효천급성발작기조환자유도담C3a수평여유도담세포총수정정상관（r=0.718, P<0.05），기산성립세포계수정정상관（r=0.495, P<0.05），거서세포계수정정상관（r=0.600, P<0.05）。결론유도담C3a수평여효천엄중정도화국부염증세포학분류상관，가능성위중요적림상표지물지도효천적치료。
Objective To investigate the clinical significance of anaphylatoxin C3a in induced sputum in patients with asthma. Methods The patients with acute exacerbation of asthma treated at our department between September, 2006 and February, 2007 were included in the study. The demographic data, medical history, levels of lung function and C3a levels in induced sputum were assessed. Results A total of 33 patients were included in the study. The level of C3a in induced sputum was significantly higher in patients with acute exacerbation of asthma (2.24 ng/ml, range 1.68-5.58 ng/ml) than that in patients with asthma remission (0.7 ng/ml, range 0.24-2.31 ng/ml, P<0.05). Sputum C3a levels in the remission patients were significantly higher than those in the healthy controls (0.12 ng/ml, range 0.07-0.39 ng/ml, P<0.05). The levels of C3a in patients with severe exacerbation (4.69 ng/ml, range 2.69-6.59 ng/ml) were significantly higher than those in patients with mild exacerbation (0.25 ng/ml, range 0.09-0.40 ng/ml) and moderate exacerbation (2.21 ng/ml, range 1.16-3.41 ng/ml) (P<0.01), and were significantly higher in patients with moderate exacerbation than in those in mild exacerbation (P<0.01). The level of C3a in induced sputum was positively correlated with the number of total cell count (r=0.718, P<0.05), eosinophils (r=0.495, P<0.05) and macrophages (r=0.600, P<0.05) in patients with acute exacerbation of asthma. Conclusion Induced sputum C3a level can serve as an important clinical biomarker for clinical asthma management.
